Redchip presentation was impressive. Silverman knows his stuff. He first went over. Q-inside for implants, vascular ports, and sizers. He mentioned database management as a potential source of revenue. If they play it right IMO, VTEQ could be THE database manager for anybody else who uses IDs, even without Q implants. In Q&A Silverman mentioned $40 million revenue potential, possibly linking up with Mentor and Allergan on breast implants.
BUT, to me the most opportunity is in the radiation dosimeter. Implanted in a tumor- breast or prostate (huge market) it can mark tumor location and measure actual dose of radiation at site. Could potentially give more precise measurements to reduce under/over dosage issues. Hot news (sarcasm)- underdose leads to insufficient treatment, and possible future metastases or enlargement of the original tumor. Overdose may reduce or eliminate a tumor but with enormous cost to patient health.
He also mentioned the increase in volume due to funding requirements, almost in a "I know it stinks, but lets just get it done and smoother sailing ahead" tone. It's nice that he recognized it vs. the "everything is peachy" approach.
Keep in mind, the email I pasted from Zacks also mentions the share increase but the math with it included still shows at 45 cents a share target.
I'm not buying based on level 2 quotes. Day traders, go for it. I'm long, period.
News 
Market Data 
Discover 
